|本期目录/Table of Contents|

[1]丁风华,陆林,潘文麒,等.血清血管形成抑制素-2水平与心肌梗死后慢性心力衰竭预后的关系[J].国际心血管病杂志,2016,06:375-378.
　DING Fenghua,LU Lin,PAN Wenqi,et al.Association between serum vasostatin-2 and prognosis of chronic heart failure after myocardial infarction[J].International Journal of Cardiovascular Disease,2016,06:375-378.
点击复制

血清血管形成抑制素-2水平与心肌梗死后慢性心力衰竭预后的关系(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2016年06期
页码:
375-378
栏目:
临床研究
出版日期:
2016-11-20

文章信息/Info

Title:
Association between serum vasostatin-2 and prognosis of chronic heart failure after myocardial infarction
作者:
丁风华; 陆林; 潘文麒; 何玉虎; 方跃华; 闫小响; 王晓群; 杨克; 张瑞岩; 沈卫峰
200025 上海交通大学医学院附属瑞金医院心内科
Author(s):
DING Fenghua;  LU Lin;  PAN Wenqi;  HE Yuhu;  FANG Yuehua;  YAN Xiaoxiang;  WANG Xiaoqun;  YANG Ke;  ZHANG Ruiyan;  SHEN Weifeng.
Department of Cardiology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China
关键词:
血管形成抑制素-2; 慢性心力衰竭; 主要心血管事件
Keywords:
Vasostatin-2;  Chronic heart failure;  Major adverse cardiac events
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2016.06.015
文献标识码:
-
摘要:
目的:评价心肌梗死后慢性心力衰竭患者的血清血管形成抑制素-2(vasostatin-2)水平与主要不良心血管事件(MACE)的关系。方法:430例心肌梗死后慢性心力衰竭患者随访3年,记录MACE情况,包括心源性死亡、再次心肌梗死、计划外再次血运重建和因顽固性心力衰竭加重再住院的复合终点。患者分为无MACE组(n=171)和MACE组(n=259)。分别检测超敏C反应蛋白、左室射血分数和血清vasostatin-2水平。结果:与无MACE组相比,MACE组vasostatin-2
Abstract:
Objective:To assess the association between serum vasostatin-2 and major adverse cardiac event(MACE)in patients with previous myocardial infarction(MI)and chronic heart failure(CHF).Method:A total of 430 patients with previous MI and CHF were followed up

参考文献/References

[1] Bouras G, Giannopoulos G, Hatzis G, et al. Inflammation and chronic heart failure: from biomarkers to novel anti-inflammatory therapeutic strategies [J]. Med Chem, 2014, 10(7): 682-699.
[2] Loh YP, Cheng Y, Mahata SK, et al.Chromogran in A and derived peptides in health and disease[J]. J Mol Neurosci, 2012, 48(2): 347-356.
[3] Lu L, Wang YN, Li MC, et al. Reduced serum levels of vasostatin-2, an anti-inflammatory peptide derived from chromogranin A, are associated with the presence and severity of coronary artery disease[J]. Eur Heart J, 2012, 33(18): 2297-2306.
[4] 张 奇,沈卫峰. 第三版心肌梗死全球定义解读[J]. 国际心血管病杂志, 2012, 39(6): 321-323.
[5] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2014[J]. 中华心血管病杂志, 2014, 42(2): 98-122.
[6] Mentz RJ, Bakris GL, Waeber B, et al. The past, present and future of renin-angiotensin aldosterone system inhibition[J]. Int J Cardiol, 2013, 167(5): 1677-1687.
[7] Laeremans H, Hackeng TM, van Zandvoort MA, et al. Blocking of frizzled signaling with a homologous peptide fragment of wnt3a/wnt5a reduces infarct expansion and prevents the development of heart failure after myocardial infarction[J]. Circulation, 2011, 124(15): 1626-1635.
[8] Tota B, Quintieri AM, Di Felice V, et al. New biological aspects of chromogranin A-derived peptides: focus on vasostatins[J]. Comp Biochem Physiol A Mol Integr Physiol, 2007, 147(1): 11-18.
[9] Singh U, Devaraj S, Jialal I. C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant[J]. Arterioscler Thromb Vasc Biol, 2005, 25(10): 2216-2221.

备注/Memo

备注/Memo:
基金项目:上海市卫生局课题(20134134) 作者单位:200025 上海交通大学医学院附属瑞金医院心内科 通信作者:陆 林,Email:rjlulin1965@163.com
更新日期/Last Update: 2016-11-20